No Data
Huangshan Capsule: Report for the third quarter of 2024
Anhui Huangshan Capsule's (SZSE:002817) Sluggish Earnings Might Be Just The Beginning Of Its Problems
Anhui Huangshan Capsule: Summary of Half-Year Report in 2024.
Anhui Huangshan Capsule: Half-year report for the year 2024.
Anhui Huangshan Capsule (002817.SZ): net income of 29.6824 million yuan in the first half of the year, a year-on-year decrease of 21.84%.
On August 16th, Gelon Hui reported the company's semi-annual report. The company achieved revenue of 235.2684 million yuan, a decrease of 7.98% compared to the same period last year. The net income attributable to shareholders of the listed company was 29.6824 million yuan, a decrease of 21.84% compared to the same period last year. The company is the first large-scale capsule manufacturer in China to have five major product series manufacturing technologies and production capabilities, including gelatin hollow capsules, enteric-coated gelatin hollow capsules, colon-soluble hollow capsules, plant hollow capsules, and plant enteric-coated hollow capsules. The company can produce 00#, 0# elongated, 0#, and 1# +
Should You Buy Anhui Huangshan Capsule Co., Ltd. (SZSE:002817) For Its Upcoming Dividend?
Anhui Huangshan Capsule Co., Ltd.'s (SZSE:002817) Popularity With Investors Under Threat As Stock Sinks 27%No Data
No Data
